Compare Pfizer Inc (PFE) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Plby Group Inc — how do they compare? Pfizer Inc trades at $28.28 (market cap $158.56B), while Plby Group Inc trades at $0.98 (market cap $118.21M). The key difference: Pfizer Inc is far larger — about 1341.3× Plby Group Inc's market cap, and Pfizer Inc pays a 6.18% dividend while Plby Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Plby Group Inc for 24 Days on average.
| PFE | PLBY | |
|---|---|---|
Market Cap | $158.56B | $118.21M |
Volume | 44,138,282 | 919,783 |
Sector | Health | Consumer Cyclical |
52-Week High | $29.02 | $2.71 |
52-Week Low | $23.67 | $0.99 |
Typical Hold Time | 158 Days | 24 Days |
Enterprise Value | $210.06B | $263.80M |
Dividend Yield | 6.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, down 0.64% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company reported revenue of $62.58B in 2025 with a net income margin of 6.8%, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline, positioning for a catalyst-rich 2026.
The stock presents a value opportunity with a forward P/E of 36.61 and consensus price target of $29.17, but faces risks from patent cliffs and volatile cash flows. Analyst sentiment is mixed with 40% buy ratings, while institutional outlook remains cautious amid earnings pressure and competitive threats in the pharma sector.
PLBY Group trades at $0.98, down 3.66% today, with a bearish technical signal from moving averages and oscillators. The company shows improving fundamentals with revenue stabilizing around $121 million and narrowing losses from -$278M in 2022 to -$13M in 2025. Recent leadership appointments signal strategic growth initiatives, while analyst consensus remains strongly positive with 75% buy ratings.
The outlook suggests cautious optimism as PLBY transitions toward profitability, projected to reach net income of $283,000 in 2026. Key risks include high debt levels with 59.52% debt-to-asset ratio and persistent negative shareholder equity. The stock offers potential upside if turnaround execution succeeds, but remains vulnerable to operational challenges and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
